FREE WEEKLY BRIEFING • METABOLIC & BARIATRIC SURGERY
MBS Digest
Closing the gaps in knowledge.
The research, pharmacotherapy, policy, and market intelligence that bariatric surgeons and obesity-medicine specialists need — distilled into one focused read every week.
Every week
A new issue, every Tuesday
100% free
No paywall, ever
For clinicians
Built for MBS teams
What you get each week
Surgery Research
Peer-reviewed studies that actually change practice — OAGB durability, SADI-S safety, magnetic anastomosis, and cancer-risk data.
Obesity Medicine
GLP-1s, tirzepatide, oral incretins, and the health-economics that increasingly drive coverage and referral decisions.
News & Market
Policy shifts, guideline updates, and the obesity-drug pipeline from Lilly, Amgen, and Pfizer — what it means for your program.
JOIN THIS WEEK'S POLL
For a patient eligible for both, which do you consider first-line for long-term cardiovascular risk reduction?
For a patient eligible for both, which do you consider first-line for long-term cardiovascular risk reduction?
ABOUT MBS DIGEST
MBS Digest is a free weekly briefing for the metabolic and bariatric surgery community — surgeons, obesity-medicine specialists, and the teams around them. We track the research, pharmacotherapy, policy, and market moves that shape practice. Questions, tips, and letters are always welcome at [email protected].
Stay ahead of metabolic medicine
One focused email a week. Always free. Unsubscribe anytime.
MBS Digest • [email protected] • Closing the gaps in knowledge.